Henry Schein, Inc. $HSIC Shares Sold by Strs Ohio

Strs Ohio trimmed its position in Henry Schein, Inc. (NASDAQ:HSIC) by 91.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,580 shares of the company’s stock after selling 27,665 shares during the period. Strs Ohio’s holdings in Henry Schein were worth $171,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Ameriprise Financial Inc. raised its stake in Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the period. Norges Bank acquired a new position in shares of Henry Schein in the second quarter worth about $89,476,000. M.D. Sass LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $79,201,000. Schroder Investment Management Group increased its position in shares of Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after purchasing an additional 936,471 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Henry Schein by 204.2% in the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after acquiring an additional 668,182 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HSIC has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Barclays began coverage on Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Wells Fargo & Company lifted their target price on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Finally, Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Henry Schein presently has a consensus rating of “Hold” and an average target price of $76.42.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $73.14 on Wednesday. The company’s fifty day moving average is $76.26 and its two-hundred day moving average is $70.87. The company has a market cap of $8.61 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.49. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%. Equities analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.